Investor relations

Investor relations

Our science-led strategy is key to delivering long-term value for patients, employees and shareholders.

NYSE: MRK
August 10, 2022 12:25 pm ET
Delayed at least 20 minutes

Latest news, events & financials

August 4, 2022

LYNPARZA® (olaparib) Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer

August 3, 2022

Merck and Eisai Provide Update on Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

August 3, 2022

Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

View all

October 27, 2022

Earnings

Merck & Co., Inc. Q3 2022 Earnings Call

Add to Calendar

February 02, 2023

Earnings

Merck & Co., Inc. Q4 2022 Earnings Call

Add to Calendar

April 27, 2023

Earnings

Merck & Co., Inc. Q1 2023 Earnings Call

Add to Calendar

August 01, 2023

Earnings

Merck & Co., Inc. Q2 2023 Earnings Call

Add to Calendar

View all

2Q22 Merck Earnings Announcement
PDF

2Q22 Merck Other Financial Disclosures
PDF

View all

Merck & Co., Inc. Q2 2022 Earnings Call

Dial: (877) 692-8955 or (234) 720-6979

Access Code: 1857604

Webcast

2Q22 Merck Earnings Presentation

2Q22 Merck Earnings Announcement

2Q22 Merck Other Financial Disclosures

Transcript

Form 10-Q

2Q22 Other Financial Disclosures (Excel)

See full agenda

Our pipeline shows our relentless pursuit of the next breakthrough.

Explore our pipeline

Phase II programs

Phase III programs

Under review

Illustration of leaders speaking on stage

Our leadership

Our deep bench of talent has the knowledge, commitment and expertise to successfully execute on our innovation strategy.

Leadership

Corporate responsibility

Supporting the future of our business and the health and well-being of patients, people and communities around the world.

Download our 2020/2021 ESG Progress Report

Download our ESG financing documents:

2021 Sustainability bond framework

Second-party opinion (SPO) on the bond framework

We're led by our science

We follow the science to our next breakthrough, leaving no stone unturned.

View our stories

Innovation

Merck’s Q2 2022 earnings report

Merck’s (NYSE: MRK) Q2 2022 results deliver robust sales growth and important clinical advancements. The company announced Q2 worldwide sales of $14.6 billion, an increase of 28% from Q2 2021. “I continue to be immensely proud of how the Merck team is performing in all facets of our business – scientifically, commercially and operationally,” said Robert […]

Next: Merck’s Q2 2022 earnings report